OSE Immunotherapeutics
Clinical-stage biotech developing immune therapies for oncology and inflammation.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Manufacturing
Description
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-05 18:30 |
OSE Immunotherapeutics annonce que plus de 90% des patients répondeurs ont main…
|
French | 347.8 KB | ||
| 2025-04-30 22:13 |
Document d'Enregistrement Universel 2024
|
French | 3.2 MB | ||
| 2025-04-30 18:00 |
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport F…
|
French | 172.4 KB | ||
| 2025-04-30 07:30 |
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie…
|
French | 266.4 KB | ||
| 2025-04-30 07:30 |
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Cen…
|
English | 272.9 KB | ||
| 2025-04-23 18:00 |
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO …
|
French | 232.6 KB | ||
| 2025-04-23 18:00 |
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présent…
|
French | 232.6 KB | ||
| 2025-04-09 07:30 |
OSE Immunotherapeutics présentera des données inédites de la période d’extensio…
|
French | 194.1 KB | ||
| 2025-04-09 07:30 |
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusve…
|
English | 177.9 KB | ||
| 2025-04-03 18:00 |
OSE Immunotherapeutics présente ses dernières avancées précliniques en Immuno-O…
|
French | 279.8 KB | ||
| 2025-04-03 18:00 |
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR …
|
English | 295.9 KB | ||
| 2025-04-03 08:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 200.4 KB | ||
| 2025-03-26 18:20 |
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le …
|
French | 412.9 KB | ||
| 2025-03-26 18:20 |
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Co…
|
English | 605.8 KB | ||
| 2025-03-11 18:00 |
OSE Immunotherapeutics et le GERCOR annoncent des premiers résultats cliniques …
|
French | 247.4 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OSE Immunotherapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
Peer Companies
